CRISPR-Cas Off-Target Analysis and Prime Editing

Prime Medicine Inc. and Integrated Dna Technologies, Inc. are listed as corporate participants, alongside research organizations such as Harvard University and The Broad Institute Inc. Prime Medicine’s activity is specifically associated with prime editing, while the broader set spans editing systems, guide design and specificity research. The dataset identifies organizations active in the topic, but does not establish that every company sells an off-target analysis product.

Harvard University has 173 documents in the recent window, while Chinese Academy of Sciences CAS has 163 and the U.S. National Institutes of Health has 132. Recent named work also involves Tsinghua University and East China Normal University, whose researchers reported Tracking-seq2 in September 2026. The leading organizations span computational prediction, guide engineering and experimental profiling.

The dataset lists $124,805,554 across 93 grants since 2020. This is a recorded grant total, not a complete estimate of commercial investment or all funding for genome editing. The listed funding rounds should be interpreted separately from this grant figure, since the round data may include broader organizational investments rather than capital dedicated specifically to this topic.

The Broad Institute Inc. leads the listed patent holders with 42 patents, followed by Harvard University with 34 and Massachusetts Institute of Technology with 22. Integrated Dna Technologies, Inc. has 18, while Prime Medicine Inc. has 7. These counts identify prominent holders in the dataset; they do not indicate the scope, status or legal strength of any individual patent.

The 24-month patent window lists 377 patents, with patent activity down 51.6% against the preceding 24 months. Publication activity shows a different direction: 2,824 publications appeared last year, up 37.8%. Together, these figures indicate that recent research output is rising even as patent filings in the measured window have declined.

Tracking-seq2, reported by East China Normal University and Tsinghua University in September 2026, aims to improve off-target profiling in primary human cells. Prime Assembly was reported in September 2026, while quadruple pegRNA was reported in April 2026; both point toward larger targeted DNA insertions. An August 2026 benchmarking study also drew attention to limits in computational off-target prediction.

The dataset groups work into 5 approaches: cell-based genome-wide profiling, in vitro cleavage assays, targeted sequencing and validation, computational prediction, and prime editor and guide engineering. Profiling searches for unintended edits across cells, while in vitro assays test cleavage under controlled conditions. Sequencing validates selected sites, prediction prioritizes candidates, and engineering aims to improve editing performance or specificity.

The United States leads with 10,124 documents, followed by China with 7,162 and the United Kingdom with 2,659. Germany has 1,923 documents and India has 1,630. These country figures show where recorded research and related activity are concentrated; they are not a measure of the quality or commercial readiness of work in each country.

Therapeutic development is the largest listed application, with 2,413 documents and 84 patents in the window. Other application areas include functional genomics and model organisms, with 1,023 documents, and inherited disease research, with 747. The dataset also identifies cancer research and agriculture and animal breeding, reflecting uses in both biomedical research and organism-level editing.